NEW YORK (GenomeWeb News) – The Beijing Institute of Genomics of the Chinese Academy of Sciences has acquired eight additional SOLiD next-generation sequencing systems from Applied Biosystems, ABI’s parent company Life Technologies said today.
BIG previously had one SOLiD system in house. It plans to use its arsenal of the nine sequencers in exploring mutation profiling of cancer genes, investigating genetic variation in model organisms, metagenomic analysis of microbes, and discovery and characterization of novel microRNAs.
According to Life Technologies, which was formed through the recent merger of ABI and Invitrogen, BIG researchers will use the systems in a wide range of large-scale resequencing and RNA analysis projects. They plan to use SOLiD system in combination with the SOLiD small RNA Expression Analysis Kit to research the role of coding and non-coding transcripts in an effort to develop RNA expression profiles in stem cells.
“By expanding our fleet of SOLiD Systems, we will benefit from the throughput, flexibility and sensitivity of these systems, which we expect will contribute greatly to major genomic initiatives, such as resequencing to identify pathogen genomics and genetics, cancer genetics, and to conduct individual research programs within the Institute,” Chung-I Wu, director of BIG, said in a statement.
Further terms were not disclosed.